— Thermo Fisher Scientific, the world leader in serving science, has announced the official opening of its new Cell and Gene Therapy (CGT) Vision Center in South Korea. This state-of-the-art facility is the latest addition to the company’s expanding global network supporting the development and commercialization of next-generation therapies.

The CGT Vision Center is strategically designed to empower biopharmaceutical companies with comprehensive solutions across the cell and gene therapy value chain—from early-stage discovery to clinical development and commercial manufacturing.

“The CGT field is driving breakthroughs in treating rare and intractable diseases, advancing personalized medicine, and shaping the future of regenerative medicine,” said Soo Jin Seok, General Manager at Thermo Fisher Scientific Korea. “These innovations require highly specialized support from discovery through commercialization. With the launch of the CGT Vision Center, we will empower our customers with access to cutting-edge technologies, regulatory expertise, and end-to-end workflow solutions—strengthening their ability to innovate and scale.”

This investment reflects Thermo Fisher’s continued commitment to advancing scientific innovation in Asia and reinforcing its leadership in cell and gene therapy solutions. The center will serve as a regional hub, offering hands-on training, process optimization support, and collaboration opportunities to fast-track the delivery of life-changing therapies.